MedTrace Logo

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

NCT05065970 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 54

Last updated 2026-04-28

Study results available
· View outcomes & findings →

Summary

Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN

Conditions

  • Immunoglobulin A (IgA) Nephropathy

Interventions

DRUG

Felzartamab

anti-CD38+ monoclonal antibody

OTHER

Placebo

Placebo comparator

Sponsors & Collaborators

  • HI-Bio, A Biogen Company

    lead INDUSTRY

Principal Investigators

  • Medical Director · HI-Bio, A Biogen Company

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-31
Primary Completion
2023-02-06
Completion
2024-05-06
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Belgium
  • Bulgaria
  • Czechia
  • Georgia
  • Germany
  • Japan
  • Malaysia
  • Philippines
  • Serbia
  • South Korea
  • Spain
  • Taiwan
  • Ukraine

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05065970 on ClinicalTrials.gov